| Literature DB >> 29739872 |
Yukimasa Takeda1, Yoshinori Harada2, Toshikazu Yoshikawa3, Ping Dai4.
Abstract
Recent studies have revealed that a combination of chemical compounds enables direct reprogramming from one somatic cell type into another without the use of transgenes by regulating cellular signaling pathways and epigenetic modifications. The generation of induced pluripotent stem (iPS) cells generally requires virus vector-mediated expression of multiple transcription factors, which might disrupt genomic integrity and proper cell functions. The direct reprogramming is a promising alternative to rapidly prepare different cell types by bypassing the pluripotent state. Because the strategy also depends on forced expression of exogenous lineage-specific transcription factors, the direct reprogramming in a chemical compound-based manner is an ideal approach to further reduce the risk for tumorigenesis. So far, a number of reported research efforts have revealed that combinations of chemical compounds and cell-type specific medium transdifferentiate somatic cells into desired cell types including neuronal cells, glial cells, neural stem cells, brown adipocytes, cardiomyocytes, somatic progenitor cells, and pluripotent stem cells. These desired cells rapidly converted from patient-derived autologous fibroblasts can be applied for their own transplantation therapy to avoid immune rejection. However, complete chemical compound-induced conversions remain challenging particularly in adult human-derived fibroblasts compared with mouse embryonic fibroblasts (MEFs). This review summarizes up-to-date progress in each specific cell type and discusses prospects for future clinical application toward cell transplantation therapy.Entities:
Keywords: chemical compound; direct reprogramming; regenerative medicine
Mesh:
Substances:
Year: 2018 PMID: 29739872 PMCID: PMC5938430 DOI: 10.1042/BSR20171650
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Schematic figure for chemical compound-based direct reprogramming of human dermal fibroblasts into desired cell types applicable for transplantation therapy
(A) Human dermal fibroblasts isolated from each patient are chemically converted into several desired cell types including neurones, neural stem/progenitor cells, brown adipocytes, cardiomyocytes, hepatocytes, and pancreatic β cells by regulating cellular signaling pathways and histone/DNA modification enzymes. iPS cells are reprogrammed by forced expression of transcription factors, then differentiated into these cells. (B) Compared with the differentiation via iPS cells, chemical compound-based direct reprogramming has a number of clear advantages for transplantation therapy, disease modeling, and drug development. In particular, the derivation and characterization of iPS cells for clinical applications still takes a long time and is expensive, so the use of autologous iPS cells derived from each patient might not be feasible. Chemical compound-based direct reprogramming is expected to rapidly convert autologous fibroblasts into desired cell types for the patients’ own transplantation. In addition, the chemically converted cells might have a lower risk for tumorigenesis compared with the cells prepared by forced expression of transcription factors as well as the cells inefficiently differentiated from iPS cells.
Summary of chemical compound-based direct reprogramming into neurones
| Target cell type | Source cells | Generation | Chemical cocktail and cytokines | Induction/maturation medium | References |
|---|---|---|---|---|---|
| Neurone (glutamatergic neurones and GABAergic neurones) | Human dermal fibroblasts | Neonatal and adult | CHIR99021, PD0325901, LDN193189, SB431542, Pifithrin-α, and Forskolin | The N2B27 medium with the chemical cocktail for several weeks | [ |
| Neurone (glutamatergic neurones and GABAergic neurones) | MEFs | Fetal | Forskolin, ISX9, CHIR99021, and I-BET151 | The neuronal induction medium with the chemical cocktail and basic fibroblast growth factor (bFGF) for 20 days. The maturation medium in co-culture of primary astrocytes or the neuronal induction medium containing Forskolin, bFGF, BDNF, GFNF for another 15 days | [ |
| Neurone (glutamatergic neurones and GABAergic neurones) | Human foreskin fibroblasts, human dermal fibroblasts | Adult | VCRFSGY: VPA, CHIR99021, RepSox, Forskolin, SP600125, GO6983, and Y-27632 | The induction medium with the chemical cocktail for 8 days. The maturation medium with CHIR99021, Forskolin, and Dorsomorphin, and extra neurotrophic factors, BDNF, GDNF, and NT3 for another 6 days | [ |
| Neurones (glutamatergic neurones) | Human primary astrocytes | Fetal | LDN193189, SB431542, TTNPB, Thiazovivin, CHIR99021, VPA, DAPT, SAG, and Purmophamine | The N2 medium with the nine chemical compounds was sequentially treated in a stepwise manner for 8 days. The neuronal differentiation medium containing three neurotrophic factors, BDNF, NT3, and IGF-1 from day 9 to 30 for the maturation | [ |
| Neurones (glutamatergic neurones) | Human primary astrocytes | Adult | VPA, CHIR99021, RepSox, Forskolin, I-BET151, and ISX-9 | The induction medium with the chemical cocktail for 20 days. The neurone maturation medium with Forskolin and I-BET151 for further culture | [ |
| Astrocytes | MEFs, human foreskin fibroblasts | Fetal | VAP, CHIR99021, SB431542, Tranylcypromine, and OAC1 | The induced astrocyte medium with fibroblast growth factor 2 (FGF2) and the chemical cocktail for 25 days (mouse) or 40 days (human) | [ |
Figure 2Schematic figure for a possible application of chemical compound-induced neurones to uncover age-associated pathological mechanism
The CiNCs are generated from human dermal fibroblasts isolated from young individuals, old individuals, and neurodegenerative disorder patients, respectively. The CiNCs might conserve donor-dependent ageing conditions, while it has been reported that iPS cells derived from the fibroblasts do not retain the ageing conditions. Comparison of transcriptome and repressive histone modifications in the induced neurones derived from young and old individuals might lead to identifying novel age-associated gene targets and the pathological mechanism underlying neurodegenerative disorders.
Summary of chemical compound-based direct reprogramming into neuronal stem/progenitor cells
| Target cell type | Source cells | Generation | Chemical cocktail and cytokines | Induction/maturation medium | References |
|---|---|---|---|---|---|
| NPCs | MEFs, mouse tail-tip fibroblasts, human urinary cells | Fetal neonatal adult | VPA, CHIR99021, and RepSox | The KSR medium (15% KSR) with the chemical cocktail for 10 days under 5% O2 condition | [ |
| Neural stem cells | MEFs. mouse tail-tip fibroblasts | Fetal adult | VPA, BIX01294, RG108, PD0325901, CHIR99021, vitamin C, and A83-01 | The stem cell culture medium with the chemical cocktail for 1 day, then the medium without the compounds for 2 days. This cycle was repeated for a total of six times. The cells were cultured in the neural stem cell medium by suspending culture for another 2 weeks | [ |
| Neural stem cells | MEFs | Fetal | A83-01, Thiazovivin, Purmophamine, and VPA | The standard NSC medium with the chemical cocktail for 10–12 days | [ |
| Neural stem cells | MEFs | Fetal | CHIR99021, LDN193189, A83-01, RG108, Parnate, SMER28, retinoic acid, Hh-Ag1.5, and bFGF | The neural reprogramming basal medium with the chemical cocktail for 14 days under 5% O2 condition. After picking up colonies, the NSC medium under normal O2 condition for further culture | [ |
| Neural stem cells | Human adipose-derived mesenchymal stem cells | Adult (23–26 years old) | SB431542, Noggin, and LDN193289 | The NSC medium containing the chemical cocktail and 3% KSR for 8 days. The B27N2 medium without EGF and fibroblast growth factor 2 (FGF2) for another 5 days. The B27N2 medium with EGF and FGF2 for another 7 days | [ |
| Neural stem cells | Primary murine astrocytes | Adult | bFGF | The N2B27 medium including bFGF for 8 days | [ |
Summary of chemical compound-based direct reprogramming into brown adipocytes and cardiomyocytes
| Target cell type | Source cells | Generation | Chemical cocktail cytokines | Induction/maturation medium | References |
|---|---|---|---|---|---|
| Brown adipocyte | C2C12 cells (mouse skeletal myoblasts) | - | Bex | The basal adipogenesis medium with Bex for 2 days. The culture under basal adipogenesis conditions for another 4 days | [ |
| Brown adipocyte | Human dermal fibroblasts | Adult (0, 38, and 49 years old) | SB431542, LDN193189, Forskolin, Dorsomorphin, and Rosiglitazone | The commercial adipocyte medium with the chemical cocktail for 3 weeks. The medium without the compounds, except for Rosiglitazone, for another 1 week | [ |
| Cardiomyocyte | MEFs | Fetal | CHIR99021, RepSox Forskolin, VPA, Parnate, and TTNPB | The Cardiac Reprogramming Medium (CRM) with the chemical cocktail for 16 days. The Cardiomyocyte-maintaining medium (CMM) with 2i (CHIR99021 and PD0325901), leukemia inhibitory factor (LIF), and insulin for another 8 days | [ |
| Cardiomyocyte | Human foreskin fibroblasts, human fetal lung fibroblasts | Neonatal fetal | CHIR99021, A83-01, BIX01294, AS8351, SC1, Y-27632, OAC2, SU16F, and JNJ10198409 | The chemical reprogramming medium (CRM) with the chemical cocktail for 6 days. The cardiac induction medium (CIM) for another 5 days. The conditioned medium incubated with H9 hESCs-derived cardiomyocytes for another 19 days | [ |
Figure 3Possible applications of chemical compound-induced cells
Chemical compound-induced cells (ciCells) rapidly prepared from autologous dermal fibroblasts can be a primary source for cell transplantation therapy. At the preclinical phase, the engraftment and tumorigenicity of ciCells need to be confirmed by using animal models for disease and injury. ciCells derived from each patient would be available as disease models to identify pathological mechanisms. Personalized medicine could be performed to select more effective drugs with lower risk for side effects using various kinds of ciCells. Thus, ciCells have a number of clear advantages for the clinical applications.
Direct reprogramming into hepatocyte-like cells by chemical compounds and exogenous gene induction
| Target cell type | Source cells | Generation | Gene induction and chemical cocktail | Induction/maturation medium | References |
|---|---|---|---|---|---|
| Hepatocyte | Rat bone-marrow derived MSCs | Adult | Tauroursodeoxycholic acid | The IMDM-based medium with tauroursodeoxycholic acid for several weeks | [ |
| Hepatocyte | MEFs | Fetal | Hnf1α and CHIR99021, A83-01 | After infection of retrovirus expressing Hnf1α, the hepatocyte culture medium with the compounds was incubated for 5 weeks | [ |
| Hepatocyte | MEFs | Fetal | Foxa1, Foxa2, or Foxa3, and VPA, CHIR99021, RepSox, Forskolin, Parnate, DZNep, TTNPB | After infection with retrovirus expressing either Foxa1, Foxa2, or Foxa3, the hepatic reprogramming medium (HRM) with the chemical cocktail was incubated for 15 days. The hepatocyte maintaining medium (HMM) with the chemical cocktail for further culture | [ |
Summary of chemical compound-based direct reprogramming into endoderm progenitor cells and somatic stem cells
| Target cell type | Source cells | Generation | Chemical cocktail cytokines | Induction/maturation medium | References |
|---|---|---|---|---|---|
| Endoderm progenitor cells | hGECs | Adult (35–78 years old) | Bix01294, RG108, Bay k 8644, and SB431542 | The DMEM-F12 based medium with the chemical cocktail using human GSEMFs (hGSEMFs) as feeder cells for 7–15 days. The DMEM-F12 based medium with A83-01, Wnt3a, and bFGF for further culture and passage | [ |
| Endoderm progenitor cells | MEFs | Fetal | RepSox, Forskolin, Y-27632, CHIR99021, TTNPB, bFGF, BMP4, and Activin A | The N2B27 medium with the chemical cocktail including TTNPB for 4 days (Stage 1). The N2B27 medium with the chemical cocktail including high concentration of CHIR99021 and Activin A instead of TTNPB for another 10 days (Stage 2). The modified medium mixed with the commercial HCM medium for further culture (Stage 3). | [ |
| Chemically induced liver progenitors (CLiPs) | Rodent primary hepatocytes | Adult | Y-27632, A83-01, and CHIR99021 | Rodent primary hepatocytes under the culture treated with the three chemicals become proliferative without obvious phenotypic alterations. | [ |
| MSC | Human dermal fibroblasts | Fetal adult | SP600125, SB202190, GO6983, Y-27632, PD0325901, and CHIR99021 | The chemical cocktail medium with the six chemicals and TGF-β1, bFGF, and LIF for 6 days. After FACS sorting, the MSC expansion medium for further culture and expansion | [ |
Summary of chemical compound-based reprogramming into induced pluripotent stem cells
| Target cell type | Source cells | Generation | Chemical cocktail cytokines | Induction/maturation medium | References |
|---|---|---|---|---|---|
| Induced pluripotent stem cells | MEFs | Fetal | VC6TF: VPA, CHIR99021, E-616452, Tranylcypromine, and Forskolin VC6TFZ: VC6TF and DZNep | The chemical reprogramming medium with the chemical cocktail (-DZNep) for 16–20 days, followed by the medium with the chemical cocktail (+DZNep) for another 12–16 days. The medium supplemented with 2i, CHIR99021 and PD0325901, and LIF for further culture | [ |
| Induced pluripotent stem cells | MEFs | Fetal | VC6TFAE: VPA, CHIR99021, E-616452, Tranylcypromine, Forskolin, AM580, and EPZ004777 VC6TFZASD: VC6TFZA and SGC0946, 5-Aza-dC | The chemical reprogramming medium with the chemical cocktail, VC6TFAE, for 16 days, followed by the medium with the chemical cocktail, VC6TFZASD, for another 12 days. The N2B27 medium with 2i (CHIR99021 and PD0325901) and LIF for another 12 days | [ |
| Induced pluripotent stem cells | Mouse neural stem cells | Fetal and postnatal | VC6TFE5: VPA, CHIR99021, E-616452, Tranylcypromine, Forskolin, EPZ004777, and Ch55 VC6TFE5Z: VC6TFE5 and DZNep | The chemical reprogramming medium with the chemical cocktail, VC6TFE5 (E-616452: 2 or 5 μM), for 20 days, followed by the medium with the chemical cocktail, VC6TFE5Z (E-616452: 5 μM), for another 20 days. The N2B27 medium with 2i CHIR99021 and PD0325901 for further culture | [ |
| Induced pluripotent stem cells | Mouse small intestinal epithelial cells | Fetal | VC6TFA: VPA, CHIR99021, E-616452, Tranylcypromine, Forskolin, and AM580 VC6TFZ: VC6TF and DZNep | The chemical reprogramming medium with the chemical cocktail, VC6TFA (E-616452: 20 μM), for 16 days, followed by the medium with the chemical cocktail, VC6TFZ (E-616452: 10 μM), for another 24 days. The N2B27 medium with 2i, CHIR99021 and PD0325901, for further culture | [ |